Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Eidos Therapeutics (Acoramidis (AG 10)), NeuraImmune Therapeutics (NI006)

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working to develop novel therapies in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Transthyretin Amyloid Cardiomyopathy Therapeutics Market.

The report provides a detailed description of the Transthyretin Amyloid Cardiomyopathy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Transthyretin Amyloid Cardiomyopathy Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Transthyretin Amyloid Cardiomyopathy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Transthyretin Amyloid Cardiomyopathy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Transthyretin Amyloid Cardiomyopathy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Transthyretin Amyloid Cardiomyopathy treatment market.

Learn More about the Clinical and Commercial Development Activities in the Transthyretin Amyloid Cardiomyopathy Therapeutics Domain:
https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Transthyretin Amyloid Cardiomyopathy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies

Request for Sample PDF to Understand More About the Transthyretin Amyloid Cardiomyopathy Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Currently, NeuraImmune Therapeutics is leading the therapeutics market with its Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drug candidates in the mid to advanced stage of clinical development.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Companies in the Therapeutics Market Include:
• Eidos Therapeutics
• NeuraImmune Therapeutics
And Many Others

Emerging and Marketed Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Therapies Covered in the Report Include:
• Acoramidis (AG 10): Eidos Therapeutics
• NI006: NeuraImmune Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Transthyretin Amyloid Cardiomyopathy Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Transthyretin Amyloid Cardiomyopathy Current Treatment Patterns
4. Transthyretin Amyloid Cardiomyopathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Transthyretin Amyloid Cardiomyopathy Late-Stage Products (Phase-III)
7. Transthyretin Amyloid Cardiomyopathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Transthyretin Amyloid Cardiomyopathy Discontinued Products
13. Transthyretin Amyloid Cardiomyopathy Product Profiles
14. Transthyretin Amyloid Cardiomyopathy Companies
15. Transthyretin Amyloid Cardiomyopathy Drugs
16. Dormant and Discontinued Products
17. Transthyretin Amyloid Cardiomyopathy Unmet Needs
18. Transthyretin Amyloid Cardiomyopathy Future Perspectives
19. Transthyretin Amyloid Cardiomyopathy Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Radiofrequency Ablation Devices Market
https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market

Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market

Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

Spinal Fusion Devices Market
https://www.delveinsight.com/report-store/spinal-fusion-devices-market

Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market

Structural Heart Devices Global Market
https://www.delveinsight.com/report-store/structural-heart-devices-market-market

Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market

Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market

Desmoplastic Small Round Cell Tumors (dsrcts) Market
https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market

Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market

Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market

Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.